Page 23 - Junshi Bioscience News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi ... Coherus BioSciences, Inc.February 1, 2021 GMT - Coherus to pay $150 million upfront for U.S. and Canada rights to toripalimab, an extensively studied, late-stage anti-PD-1 antibody - First U.S. BLA filing expected this year for nasopharyngeal carcinoma with breakthrough therapy designation - Options to PD-1 combination agents, TIGIT and IL-2, add long-term growth potential - Conference call at 8:00 ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 ... Junshi BiosciencesFebruary 1, 2021 GMT Junshi Biosciences to receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option programs (if exercised) in US and Canada The first toripalimab BLA to be filed with the US FDA for nasopharyngeal carcinoma later this year SHANGHAI, China, Feb. 01, 2021 ...

Junshi Biosciences Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada Junshi Biosciences to receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option programs (if exercised) in US and Canada The first toripalimab BLA to be filed with the US FDA for nasopharyngeal ca...

Coherus is discontinuing the development of CHS-2020 (Eylea ® biosimilar candidate) and will direct those capital and development resources to the toripalimab monotherapy and combinations program. Terms of the Coherus – Junshi Biosciences collaboration Under the terms of the agreement, Coherus will pay $150 million upfront for exclusive rights to toripalimab in the United States and Canada, options in these territories to Junshi Biosciences’ anti-TIGIT antibody and next-generation engineered IL-2 cytokine, and certain negotiation rights to two undisclosed preclinical immuno-oncology drug...

1 feb 2021 Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada Junshi Biosciences to receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option programs (if exercised) in US and Canada The first toripalimab BLA to be filed with the US FDA for nasopharyngeal carcinoma later this year SHANGHAI, China, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-dri...